Life Science investing is different from Tech investing. There are hurdles faced in testing and clinical trials that don’t have a comparison in the Technology silo. Companies raising money within the Life Sciences silo may need to go through several series of funding and can travel very different journeys to get to an exit. In addition, within Life Science, the strategy of the startup company can differ based on how they choose to navigate the path to exit.
David Baker is a Co-Founder of Vallon Pharmaceuticals and has over 25 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. He has been directly involved with the commercialization of five medications with annual sales in excess of $1 billion each, including Adderall XR® and Vyvanse®, the two most successful ADHD brands based on annual revenue.
In 2017, while serving as the interim CEO of Alcobra Ltd, a NASDAQ listed pharmaceutical company based in Tel Aviv and Philadelphia, David led Alcobra through the successful merger with Arcturus Therapeutics (NASDAQ: ARCT). He also successfully completed the out license of ADAIR, an early stage drug for the treatment of ADHD, which became the basis for forming Vallon Pharmaceuticals which he now leads.